Journal of Diabetes Research (Jan 2015)

Angioblast Derived from ES Cells Construct Blood Vessels and Ameliorate Diabetic Polyneuropathy in Mice

  • Tatsuhito Himeno,
  • Hideki Kamiya,
  • Keiko Naruse,
  • Zhao Cheng,
  • Sachiko Ito,
  • Taiga Shibata,
  • Masaki Kondo,
  • Jiro Kato,
  • Tetsuji Okawa,
  • Atsushi Fujiya,
  • Hirohiko Suzuki,
  • Tetsutaro Kito,
  • Yoji Hamada,
  • Yutaka Oiso,
  • Kenichi Isobe,
  • Jiro Nakamura

DOI
https://doi.org/10.1155/2015/257230
Journal volume & issue
Vol. 2015

Abstract

Read online

Background. Although numerous reports addressing pathological involvements of diabetic polyneuropathy have been conducted, a universally effective treatment of diabetic polyneuropathy has not yet been established. Recently, regenerative medicine studies in diabetic polyneuropathy using somatic stem/progenitor cell have been reported. However, the effectiveness of these cell transplantations was restricted because of their functional and numerical impairment in diabetic objects. Here, we investigated the efficacy of treatment for diabetic polyneuropathy using angioblast-like cells derived from mouse embryonic stem cells. Methods and Results. Angioblast-like cells were obtained from mouse embryonic stem cells and transplantation of these cells improved several physiological impairments in diabetic polyneuropathy: hypoalgesia, delayed nerve conduction velocities, and reduced blood flow in sciatic nerve and plantar skin. Furthermore, pathologically, the capillary number to muscle fiber ratios were increased in skeletal muscles of transplanted hindlimbs, and intraepidermal nerve fiber densities were ameliorated in transplanted plantar skin. Transplanted cells maintained their viabilities and differentiated to endothelial cells and smooth muscle cells around the injection sites. Moreover, several transplanted cells constructed chimeric blood vessels with recipient cells. Conclusions. These results suggest that transplantation of angioblast like cells induced from embryonic stem cells appears to be a novel therapeutic strategy for diabetic polyneuropathy.